icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 21-02 – STUDY TITLE – Patient Reported Outcomes in patients receiving DVd for relapsed multiple myeloma.

In Australia, the combination of Daratumumab, bortezomib and dexamethasone (DVd) was approved by the PBAC for Pharmaceutical Benefit Scheme (PBS) listing for the treatment of Myeloma at first relapse in February 2021. The purpose of this study is to evaluate the real-life tolerability, impact on quality of life and overall treatment satisfaction of this regimen in patients enrolled on the Myeloma and related diseases registry (MRDR).

 

STATUS

Actively recruiting

 

CURRENT ENROLMENT

16 Patients

Recruitment updated as of November 2022

 

STUDY DESIGN

Information on patient-reported outcomes will be collected at various time points using the following two questionnaires: TSQM-9 and MyPOS.

These questionnaires are available in the following languages:

  • English

  • Arabic

  • Greek

  • Serbian

  • Vietnamese

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

 

TIME FRAME

2021 – 2024

 

PARTICIPANTS

Patients enrolled on the Myeloma and Related Diseases Registry (MRDR) with relapsed refractory multiple myeloma following one prior line of therapy and are currently receiving daratumumab, bortezomib and dexamethasone from the PBS for treatment of progressive disease.

 

SITE LOCATIONS